First Immunotherapy for Type 1 Diabetes Approved in the UK

For the first time, the UK has licensed an immunotherapy drug designed to delay type 1 diabetes. Teplizumab, also known as Tzield, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) after a thorough review of evidence from clinical trials.

Unlike insulin or other diabetes management tools, teplizumab addresses what drives type 1 diabetes in the first place: the immune system mistakenly attacking the beta cells that produce insulin. By slowing this immune attack, the drug can help preserve these cells and postpone the onset of type 1 diabetes.

Teplizumab is approved for people aged 8 and over who are in the very early stages of type 1 diabetes, before symptoms develop and the condition fully emerges. This means treatment targets people identified as at-risk through screening—often family members of those with type 1 diabetes or individuals showing early immune markers.

The drug is not intended for people already diagnosed with type 1 diabetes or those without signs of the early immune process.

Clinical trials demonstrated that teplizumab can delay the development of type 1 diabetes by around three years on average. The MHRA determined the drug met safety and effectiveness standards required for licensing.

It is important to note that teplizumab delays type 1 diabetes—it does not prevent or cure it. Over time, the immune attack typically continues, and most people will eventually develop the condition.

This approval marks a significant shift in how type 1 diabetes is approached. In 1979, UK researchers first discovered that modifying the immune response could alter the course of type 1 diabetes. That finding launched a new era of research focused on understanding and targeting the immune attack.

The National Institute for Health and Care Excellence (NICE) has approved teplizumab for NHS use. However, as of now, the drug is not yet routinely available through the NHS, though the pathway has been established for future access.

Origin: diabetes.org.uk (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.